Improving immune responses against aggressive B-cell lymphomas
Official title: Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy
Funded at Weill Medical Coll of Cornell Univ · NIH-10929491 · Data updated 2026-11-12
This study is looking at a new treatment that helps your immune system fight diffuse large B-cell lymphoma (DLBCL) by targeting a protein called MALT1, and it may offer better results for patients like you who are receiving immunotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 14, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $454,625 |
| NIH project number | 5R01CA282889-02 |
| Project ID | NIH-10929491 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with diffuse large B-cell lymphoma who have not responded well to existing therapies.
✕Less likely to help
Patients with other types of lymphoma or those who have already had extensive treatment may not benefit from this research.
What this research studies
This research focuses on enhancing the immune system's ability to fight diffuse large B-cell lymphoma (DLBCL), a common and aggressive type of non-Hodgkin lymphoma. The approach involves targeting a specific protein called MALT1, which plays a crucial role in the growth of lymphoma cells and the suppression of anti-tumor immunity. By using a newly developed MALT1 inhibitor, the research aims to disrupt the signals that promote lymphoma growth and improve the effectiveness of immunotherapy treatments. Patients may be involved in trials testing this innovative treatment to see if it can lead to better outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with aggressive B-cell lymphomas, potentially improving survival rates.
How similar studies have gone: Previous research has shown promise in targeting MALT1 in other contexts, indicating potential for success in this novel application.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Zappasodi, Roberta — Weill Medical Coll of Cornell Univ
- Study coordinator: Zappasodi, Roberta
Related research
Other NIH-funded projects on the same topics.
-
Targeting the IL-1R Pathway to Boost Immunotherapy for Anaplastic Large Cell Lymphoma
Aims to make CD30 CAR therapies work better for people with ALCL by blocking a immune-evasion pathway.
-
Immunotherapy for B-cell lymphoma using NK T cells
A patient-focused immunotherapy approach using natural killer T cells engineered to target B-cell lymphoma, potentially offering off-the-shelf treatment options.
-
Targeting MALT1 to Strengthen Anti-Lymphoma Immunity and Boost Immunotherapy
Aims to improve treatment for a common type of B-cell lymphoma by blocking a specific protein (MALT1) to enhance the body's immune attack and response to existing therapies.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
NKT cell therapy for B‑cell lymphoma
This project offers an off‑the‑shelf immune cell treatment using engineered natural killer T (NKT) cells for adults with B‑cell non‑Hodgkin lymphoma.
-
Blocking MALT1 to boost the immune attack against aggressive B‑cell lymphoma
Seeing if drugs that block a protein called MALT1 can help the immune system and improve immunotherapy for adults with aggressive diffuse large B‑cell lymphoma (DLBCL).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.